GRAIL, Inc. (GRAL) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Ongoing Losses ⢠Weak Efficiency GRAL has a strong balance sheet and low leverage, but persistent operating losses, negative cash flow, and poor efficiency keep the investment case under pressure.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Resistance test ⢠Volatile rebound Support Level: $45.63â$46.90 Resistance Level: $54.99 GRAL is showing a constructive rebound over the last month, but it remains volatile and faces near-term resistance around $54.99 that could cap further upside without a decisive breakout.
Sentiment & News
Key News Insights: ⢠Commercial expansion ⢠Trial setback ⢠Insider selling GRAIL's April news was mixed, with new commercial partnerships and upcoming ASCO data offset by a major stock selloff, trial disappointment, insider sales, and investor probes.
AI Summary
GRAL has shifted from a high-potential screening story to a prove-it-now investment, where strong liquidity and improving gross margins buy time but the NHS endpoint miss means future clinical, reimbursement, and adoption updates must decisively rebuild credibility for the stock to sustain upside.
Description
GRAIL, Inc. is a biotechnology firm based in Menlo Park, California, established in 2015. The company develops blood-based tests intended to detect cancer at early stages in asymptomatic individuals and to support faster diagnostic resolution when cancer is suspected, as well as tests for minimal residual disease and other post-diagnostic uses. GRAIL previously operated as a subsidiary of Illumina, Inc.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 26 | Dec 3 | GRAL | GRAIL, Inc. | Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside. | Closed | -8.1% |